Last updated on July 2019

Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG


Brief description of study

The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.

Clinical Study Identifier: NCT02684058

Find a site near you

Start Over

Children's Mercy Hospital

Kansas City, MO United States
  Connect »

Phoenix Children's Hospital

Phoenix, AZ United States
  Connect »

Children s National Hospital

Washington, WA United States
  Connect »

Children s Mercy Hospital

Kansas City, MO United States
  Connect »

Novartis Investigative Site

Marseille Cedex 5, France
  Connect »

Phoenix Childrens Hospital

Phoenix, AZ United States
  Connect »

Novartis Investigative Site

Moscow, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.